Class summary at a glance.

Every drug in the Tissue-nonspecific Alkaline Phosphatase class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 1tracked in Part D
CY24 Part D spend: $542.9Mcombined across class
Total Rx claims: 5K602 unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Asfotase Alfa

Brand: STRENSIQ · 5K Part D claims (CY24) · 602 beneficiaries · First FDA approval: 2015-10-23

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend $542.9M

Class share

100%

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.